Clinical Report: Antibody-Drug Conjugates in Colorectal Cancer Overview

Background

Colorectal cancer is a leading cause of cancer-related mortality worldwide, with limited treatment options for advanced stages. Antibody-drug conjugates represent a novel therapeutic approach that aims to deliver cytotoxic agents directly to tumor cells, potentially reducing systemic toxicity. Understanding the current clinical trial landscape for ADCs in CRC is crucial for identifying research gaps and future directions.

Data Highlights

Key Findings

• 194 non-observational ADC trials for CRC were identified.
• Trial numbers have increased since 2020, peaking in 2024.
• Most trials are open-label and industry-sponsored, primarily conducted in China and the United States.
• HER2, Trop-2, and c-Met are the most frequently studied targets.
• Topoisomerase I inhibitors are the most common payloads used in these trials.
• Safety and tolerability are the primary endpoints for the majority of trials.

Clinical Implications

The findings highlight the need for continued research into ADCs for CRC, particularly in identifying novel targets and optimizing therapeutic strategies. Clinicians should remain aware of the early-phase nature of current trials and the associated focus on safety.

Conclusion

While ADCs show preliminary potential in treating advanced colorectal cancer, caution is warranted regarding their efficacy due to the early-stage nature of the trials. Future research will be essential to address existing challenges and enhance treatment options.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges
2. The ASCO Post, 2021 -- Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
3. The ASCO Post, 2020 -- More Antibody-Drug Conjugates on the Horizon for Breast Cancer
4. OncoDaily, 2026 -- ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer
5. The ASCO Post — Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes
6. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
7. Colorectal Cancer Targeted Therapy | Targeted Drugs for Colorectal Cancer | American Cancer Society
8. ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer - OncoDaily
9. https://crain-platform-precisiononcologynews-prod.s3.amazonaws.com/2025-04/NCCN%20colon%20DPYD%20update%20033125.pdf
10. Scholars@Duke publication: Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
11. DESTINY-CRC02 Trial Results at ESMO 2025: Trastuzumab Deruxtecan Consolidates Role in HER2-Positive mCRC - OncoDaily
12. Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Metastatic Colorectal Cancer
13. EudraCT Number 2020-004782-39 - Clinical trial results - EU Clinical Trials Register
14. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer - PMC
15. Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial - PubMed
16. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies